RecruitingPhase 1Phase 2NCT06810778

Duvelisib and Venetoclax in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

Phase I/II Study of Duvelisib and Venetoclax in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

Sponsor

Jonsson Comprehensive Cancer Center

Enrollment

12 participants

Start Date

May 2, 2025

Study Type

INTERVENTIONAL

Summary

This is an open-label, phase I/II study of duvelisib in combination with Venetoclax for patients with relapsed/refractory NHL. Duvelisib is an FDA approved, marketed product used to treat certain patients with leukemia and lymphoma and Venetoclax, which is approved for treatment of certain patients with acute myeloid leukemia. The combination of these two drugs is experimental. Experimental means that it is not approved by the United States Food and Drug Administration (FDA). The researchers want to find out how safe it is to combine these drugs and how well this combination can work for your cancer.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is testing a combination of two targeted cancer drugs — duvelisib and venetoclax — for patients with certain blood cancers (such as chronic lymphocytic leukemia or follicular lymphoma) that have come back or stopped responding to treatment. **You may be eligible if...** - You have been diagnosed with relapsed (came back) or refractory (stopped responding) CLL, SLL, or follicular lymphoma - You have already received prior cancer treatments - You are in good enough health to tolerate the study drugs - You meet the blood count and organ function requirements **You may NOT be eligible if...** - You have serious active infections (including certain fungal infections) - You have received prior treatment with both duvelisib and venetoclax - You have significant liver or heart problems - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGDuvelisib

15 and 25 mg BID

DRUGVenetoclax

200, 400, and 800 mg QD

Locations(1)

David Geffen School of Medicine at the University of California at Los Angeles

Los Angeles, California, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06810778